Fast Interneuron Dysfunction in Laminar Neural Mass Model Reproduces Alzheimer's Oscillatory Biomarkers

Alzheimers disease (AD) is characterized by a progressive cognitive decline underpinned by disruptions in neural circuit dynamics. Early-stage AD is associated with cortical hyperexcitability, whereas later stages exhibit oscillatory slowing and hypoactivity, a progression observable in electrophysiological spectral characteristics. While previous studies have linked these changes to the dysfunction of fast-spiking parvalbumin-positive (PV) interneurons and neuronal loss associated with amyloid-beta (A{beta}) and hyperphos-phorylated tau (hp-{tau}) pathology, the precise mechanistic relationship between cellular and altered electrophysiology remains unclear. To study this relationship, we employed a Laminar Neural Mass Model that integrates excitatory and inhibitory neural populations within a biophysically informed columnar framework. The connectivity constant from PV cells to pyramidal neurons was gradually reduced to simulate the progressive neurotoxic effects of A{beta} oligomers. Other model parameters were systematically varied to compare with existing modeling literature and also to simulate the effects of hp-{tau}. All model predictions were compared to empirical M/EEG findings in the literature. Our simulations of PV interneuron dysfunction successfully reproduced the biphasic electrophysiological progression observed in AD: an early phase of hyperexcitability with increased gamma and alpha power, followed by oscillatory slowing and reduced spectral power. Alternative mechanisms and model parameters, such as increased excitatory drive, failed to replicate the observed biomarker trajectory. Additionally, to reconcile the hypoactivity and decreased firing rates observed in advanced AD stages, we combined the PV dysfunction model with a disruption of the pyramidal cell populations that reflects the neurotoxicity induced by hp-{tau}. Although this additional mechanism is not necessary to reproduce oscillatory changes in the isolated neural mass, it is crucial for aligning the model with evidence of reduced firing rates, metabolic activity, and cell loss and will enhance its applicability in future whole-brain modeling studies. These results support the hypothesis that at the local level, PV interneuron dysfunction is a primary driver of cortical electrophysiological alterations, while pyramidal neuron loss underlies later-stage severe hypoactivity. Our model provides a mechanistic framework for interpreting excitation-inhibition imbalance across AD progression, demonstrating the value of biophysically constrained models for interpreting electrophysiological biomarkers. Author summaryAlzheimers disease (AD) is not just a disorder of memory--it is a disease of brain networks. Before widespread neuronal loss occurs, the brain enters a state of hyperexcitability, which may contribute to disease progression. This hyperactivity is thought to arise from the selective dysfunction of inhibitory interneurons, particularly parvalbumin-positive (PV) interneurons, which play a crucial role in maintaining balanced brain activity. However, as the disease advances, a dramatic shift occurs, with neurons becoming progressively less active, leading to network breakdown. Understanding how this transition unfolds is essential for identifying new targets for early intervention. In this study, we developed a computational model of AD that represents the effects of amyloid-beta (A{beta}) oligomers and hyperphosphorylated tau (hp-{tau}) on neural circuits in a biologically meaningful way. Our model reproduces key features of M/EEG biomarkers, demonstrating that PV interneuron dysfunction leads to early hyperexcitability and the electrophysiological oscillatory changes characteristic of AD, while pyramidal cell pathology is necessary to drive later hypoactivity and network failure. By bridging molecular pathology mechanisms with mesoscale neural activity, our model provides a powerful tool for studying AD-related circuit dysfunction. It also highlights the importance of PV interneurons as a potential therapeutic target, paving the way for biologically informed interventions that could alter the course of the disease.